A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
over the course of study
Judy H Chiao, MD
Cyclacel Pharmaceuticals, Inc.
United States: Food and Drug Administration
|Roswell Park Cancer Institute||Buffalo, New York 14263|
|South Texas Accelerated Research Therapeutics||San Antonio, Texas 78229|